SCHEMBL17474384

SCHEMBL17474384

Cc1ccc(S(=O)(=O)N2CCCC(=O)C2c2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.60
MMP2 P08253 1/20 0.57
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 1/20 0.48
HSD11B1 P28845 1/20 0.48
GAA P10253 2/20 0.47
TSHR P16473 2/20 0.47
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
TAS2R14 Q9NYV8 2/20 0.45
MCOLN3 Q8TDD5 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
FKBP1A P62942 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16071190 1.00 NPSR1 (0.60) NPSR1MMP2MAPTALDH1A1SMN1; SMN2
SCHEMBL17870938 0.83 MMP2 (0.62) NPSR1MMP2MAPTALDH1A1SMN1; SMN2
SCHEMBL17870939 0.83 MMP2 (0.62) NPSR1MMP2MAPTALDH1A1SMN1; SMN2
SCHEMBL16056291 0.83 L3MBTL1 (0.47) NPSR1MMP2MAPTALDH1A1SMN1; SMN2
SCHEMBL18264405 0.79 MEN1 (0.51) NPSR1MMP2MAPTALDH1A1GAA
SCHEMBL28149879 0.78 NPSR1 (0.59) NPSR1MMP2MAPTALDH1A1SMN1; SMN2
SCHEMBL6177618 0.77 PSEN1 (0.69) NPSR1MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL6177624 0.77 PSEN1 (0.69) NPSR1MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL14068809 0.74 NPSR1 (0.61) NPSR1MMP2MAPTALDH1A1SMN1; SMN2
SCHEMBL16056695 0.74 MMP2 (0.57) NPSR1MMP2MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9505718-B2 3-piperidone compounds and their use as neurokinin-1 (NK1) receptor antagonists NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-11-29 US disclosed
US-9505718-B2 3-piperidone compounds and their use as neurokinin-1 (NK1) receptor antagonists NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-11-29 US disclosed
US-9505718-B2 3-piperidone compounds and their use as neurokinin-1 (NK1) receptor antagonists NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-11-29 US disclosed
US-20160031817-A1 3-PIPERIDONE COMPOUNDS AND THEIR USE AS NEUROKININ-1 (NK1) RECEPTOR ANTAGONISTS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-02-04 US disclosed
US-20160031817-A1 3-PIPERIDONE COMPOUNDS AND THEIR USE AS NEUROKININ-1 (NK1) RECEPTOR ANTAGONISTS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-02-04 US disclosed
US-20160031817-A1 3-PIPERIDONE COMPOUNDS AND THEIR USE AS NEUROKININ-1 (NK1) RECEPTOR ANTAGONISTS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031817-A1 3-PIPERIDONE COMPOUNDS AND THEIR USE AS NEUROKININ-1 (NK1) RECEPTOR ANTAGONISTS TACR1, NPSR1, TACR2 NPSR1 2/4885MMP2 3367/4885MAPT 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.